Lacipil

Lacidipine, the active ingredient in Lacipil, is a calcium channel blocker presented as a tablet for oral use. It treats hypertension in adults by lowering blood pressure and reducing vascular resistance. GNH USA supplies Lacipil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacidipil is a dihydropyridine calcium channel blocker used to manage high blood pressure conditions.

Hypertension: reduces systemic vascular resistance to lower blood pressure. Essential hypertension: provides sustained blood pressure control in primary hypertension. Isolated systolic hypertension: helps lower elevated systolic pressure in older patients.

Adverse reactions may occur with lacidipine therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness. - Peripheral edema: swelling of ankles or feet. - Dizziness: especially upon standing. - Tachycardia: increased heart rate. - Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Angioedema: swelling of face, lips, or airway. - Hepatic dysfunction: elevated liver enzymes. - Myocardial infarction: rare cardiac event. - Arrhythmia: abnormal heart rhythms. - Allergic reaction: rash, itching, or anaphylaxis.

Patients should be counseled on safety considerations before starting lacidipine. - Blood pressure monitoring: check values before initiation and regularly thereafter. - Renal impairment: use with caution and monitor renal function. - Hepatic disease: consider dose adjustment or avoid if severe. - Concomitant antihypertensives: risk of additive hypotension. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at ambient temperature: keep in original container, protect from moisture and light.

Lacidipine may interact with several drug classes.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampicin): reduce therapeutic effect. - Grapefruit juice: may elevate drug levels.

Moderate Interactions (Monitor Closely):\n- Other antihypertensives: additive blood pressure lowering. - Diuretics: potential electrolyte disturbances. - Beta‑blockers: may mask tachycardia response.